Geneva, Switzerland (PRWEB) April 19, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs announced today the Company’s Chief Technology Officer, Armelle Gaussin, PhD, will be speaking on Rapidly Identifying Relevant Monoclonal Antibody Variants at the 2011 PEGS Summit on Wednesday, May 11, 2011 at the Sheraton Boston Hotel in Boston, Massachusetts. Selexis will also be exhibiting at the conference, May 9 – 13, 2011.
Dr. Gaussin’s lecture, “Exploiting Potent Chromatin Remodeling Elements to Rapidly Identify Relevant Monoclonal Antibody Variants in Stable CHO Cell Lines” is part of the Antibody Discovery Strategies and Tools track. Conference attendees can hear Dr. Gaussin’s lecture on Wednesday, May 11 at 11:10 AM.
DNA vectors incorporating versatile epigenetic regulatory elements such as the Selexis Genetic Elements (SGEs) provide high transcription rates and prevent transgene silencing, yielding cell clones with increased and stable expression. Thus, combined with optimized gene transfer methods, these vectors can be used to generate high-producer stable cell lines in short time frames and with little screening efforts. This unique feature opens up the possibility of relying on a single stable expression system throughout the drug development process, allowing the identification of relevant monoclonal antibody variants and high expressing clones at the same time. This novel set up allows considerable time and labour saving by screening top lead candidates in a production ready platform.
Additionally, conference attendees can meet Selexis representatives at Booth 408, May 9 – 13. To schedule meetings in advance, please contact Selexis at email@example.com
Registration for the PEGS conference is required. For more information, visit http://www.pegsummit.com/
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvarient Screening™ and the proprietary Selexis SURECHO-M Cell Line™.
For more information, visit http://www.selexis.com